Almond, Mark
Farne, Hugo A. http://orcid.org/0000-0003-2556-3953
Jackson, Millie M.
Jha, Akhilesh
Katsoulis, Orestis
Pitts, Oliver
Tunstall, Tanushree
Regis, Eteri http://orcid.org/0000-0001-9862-2147
Dunning, Jake
Byrne, Adam J.
Mallia, Patrick
Kon, Onn Min
Saunders, Ken A. http://orcid.org/0000-0002-9284-1100
Simpson, Karen D.
Snelgrove, Robert J.
Openshaw, Peter J. M. http://orcid.org/0000-0002-7220-2555
Edwards, Michael R.
Barclay, Wendy S. http://orcid.org/0000-0002-3948-0895
Heaney, Liam M. http://orcid.org/0000-0002-8791-0167
Johnston, Sebastian L. http://orcid.org/0000-0003-3009-9200
Singanayagam, Aran http://orcid.org/0000-0001-9849-0033
Funding for this research was provided by:
RCUK | Medical Research Council (MR/V000098/1)
Article History
Received: 22 June 2023
Accepted: 11 October 2023
First Online: 19 October 2023
Competing interests
: S.L.J. has personally received consultancy fees from AstraZeneca, Bioforce, Enanta, Myelo Therapeutics GmbH, Bayer, Lallemand Pharma, Synairgen, Novartis, Boehringer Ingelheim, Chiesi, GlaxoSmithKline, and Centocor. S.L.J. is an inventor of patents on the use of inhaled interferons for treatment of exacerbations of airway diseases and on rhinovirus vaccines. S.L.J. is the Director and shareholder of Virtus Respiratory Research Ltd. A.S. has received honoraria for speaking from AstraZeneca. A.J. held a clinical lectureship at the University of Cambridge that was supported jointly by the University of Cambridge Experimental Medicine Training Initiative (EMI) programme in partnership with GlaxoSmithKline (EMI-GSK) and Cambridge University Hospitals NHS Foundation Trust. K.D.S. and K.A.S. are both employees of, and own shares in GSK. PJMO reports grants from the EU Innovative Medicines Initiative (IMI) 2 Joint Undertaking, grants from UK Medical Research Council, GlaxoSmithKline, Wellcome Trust, EU-IMI, UK, National Institute for Health Research, and UK Research and Innovation-Department for Business, Energy and Industrial Strategy; and personal fees from Pfizer, Janssen, and Seqirus. A.J.B. has received consultancy fees from Ammax, Devpro, and Ionis pharmaceuticals, via his institution. The remaining authors declare no competing interests.